Skip to main content
Springer Nature Link
Log in

Radiotherapy is superior to transarterial chemoembolization as adjuvant therapy after narrow-margin hepatectomy in patients with hepatocellular carcinoma: A single-center prospective randomized study

  • Research
  • Published:
Langenbeck's Archives of Surgery Aims and scope Submit manuscript

Abstract

Background

This study was recruited to compare the efficacy and safety of radiotherapy (RT) and transarterial chemoembolization (TACE) as postoperative adjuvant therapy after narrow-margin hepatectomy in hepatocellular carcinoma (HCC) patients.

Methods

This single-center prospective randomized study was conducted in the Cancer Hospital, Guang Xi Medical University, Nanning. A total of 72 patients who received treatment in this hospital between August 2017 and July 2019 were included and randomly allocated to TACE group (n = 48) and RT group (n = 24). Next, overall survival (OS) and progression-free survival (PFS) rates, recurrence patterns, financial burden, and safety were evaluated.

Results

The difference between the RT and TACE groups was not significant in one-, three-, and five-year OS (87.5%, 79.0%, and 62.5% vs. 93.8%, 75.9%, and 63.4%, respectively, P = 0.071) and PFS rates (79.0%, 54.2%, and 22.6% vs. 75.0%, 47.9%, and 32.6%, respectively, P = 0.071). Compared to the TACE group, the RT group had significantly lower intrahepatic recurrence rate (20.8% vs. 52.1%, P = 0.011), higher extrahepatic recurrence rate (37.5% vs. 14.6%, P = 0.034), and no marginal and diffuse recurrences (0% vs. 16.7%, P < 0.05). The mean overall treatment cost was higher (¥62,550.59 ± 4397.27 vs. ¥40,732.56 ± 9210.54, P < 0.01), the hospital stay (15.1 ± 3.7 vs. 11.8 ± 4.1 days, P < 0.01) was longer, and the overall treatment stay (13.3 ± 5.3 vs. 41.29 ± 12.4 days, P < 0.01) was shorter in the TACE group than in the RT group. Besides, both groups did not exhibit significant differences in the frequency and severity of adverse events.

Conclusion

Both adjuvant TACE and RT can better the OS and PFS of patients with HCC. However, RT has a significantly better performance than TACE in terms of improving intrahepatic recurrence rate, treatment cost and hospital stay.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

Data availability

All the data analyzed in this study are obtained from the original articles.

References

  1. Feng R, Su Q, Huang X, Basnet T, Xu X, Ye W (2023) Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration? Cancer Commun (Lond) 43(1):75–86

    Article  PubMed  Google Scholar 

  2. Torimura T, Iwamoto H (2022) Treatment and the prognosis of hepatocellular carcinoma in Asia. Liver Int 42(9):2042–2054

    Article  PubMed  Google Scholar 

  3. Goh BKP, Chua DW, Koh YX, Tan EK, Kam JH, Teo JY et al (2021) Continuous improvements in short and long-term outcomes after partial hepatectomy for hepatocellular carcinoma in the 21st century: single institution experience with 1300 resections over 18 years. Surg Oncol 38:101609

    Article  PubMed  Google Scholar 

  4. Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M et al (2015) Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 16(13):1344–1354

    Article  CAS  PubMed  Google Scholar 

  5. Shi C, Li Y, Geng L, Shen W, Sui C, Dai B, Lu J, Pan M, Yang J (2022) Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: a randomised controlled trial. Eur J Cancer 166:176–184

    Article  CAS  PubMed  Google Scholar 

  6. Yang J, Liang H, Hu K, Xiong Z, Cao M, Zhong Z, Yao Z, Deng M (2021) The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis. Cancer Cell Int 21(1):92

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Akateh C, Black SM, Conteh L, Miller ED, Noonan A, Elliott E, Pawlik TM, Tsung A, Cloyd JM (2019) Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol 25(28):3704–3721

    Article  PubMed  PubMed Central  Google Scholar 

  8. Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS et al (2020) Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO MOS and SSO. Ann Oncol 31(3):334–351

    Article  PubMed  Google Scholar 

  9. Miao XY, Hu JX, Dai WD, Zhong DW, Xiong SZ (2011) Null-margin mesohepatectomy for centrally located hepatocellular carcinoma in cirrhotic patients. Hepatogastroenterology 58(106):575–582

    PubMed  Google Scholar 

  10. Nara S, Shimada K, Sakamoto Y, Esaki M, Kishi Y, Kosuge T, Ojima H (2012) Prognostic impact of marginal resection for patients with solitary hepatocellular carcinoma: evidence from 570 hepatectomies. Surgery 151(4):526–536

    Article  PubMed  Google Scholar 

  11. Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y et al (2004) Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 101(4):796–802

    Article  PubMed  Google Scholar 

  12. Liu L, Shui Y, Yu Q, Guo Y, Zhang L, Zhou X, Yu R, Lou J, Wei S, Wei Q (2020) Narrow-margin hepatectomy resulted in higher recurrence and lower overall survival for R0 resection hepatocellular carcinoma. Front Oncol 10:610636

    Article  PubMed  Google Scholar 

  13. Chen B, Wu JX, Cheng SH, Wang LM, Rong WQ, Wu F et al (2021) Phase 2 study of adjuvant radiotherapy following narrow-margin hepatectomy in patients with HCC. Hepatology 74(5):2595–2604

    Article  PubMed  Google Scholar 

  14. Gou XX, Shi HY, Li C, Chen ZL, Ouyang W, Sun LY et al (2022) Association of adjuvant radiation therapy with long-term overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a multicenter propensity-matched study. Int J Radiat Oncol Biol Phys 114(2):238–249

    Article  PubMed  Google Scholar 

  15. Wang WH, Wang Z, Wu JX, Zhang T, Rong WQ, Wang LM et al (2015) Survival benefit with IMRT following narrow-margin hepatectomy in patients with hepatocellular carcinoma close to major vessels. Liver Int 35(12):2603–2610

    Article  PubMed  Google Scholar 

  16. Wang L, Qiu L, Ke Q, Ji H, Wu J (2022) Systematic review of adjuvant external beam radiotherapy for hepatocellular carcinoma following radical hepatectomy. Radiother Oncol 175:101–111

    Article  PubMed  Google Scholar 

  17. Wang Z, Ren Z, Chen Y, Hu J, Yang G, Yu L et al (2018) Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study. Clin Cancer Res 24(9):2074–2081

    Article  CAS  PubMed  Google Scholar 

  18. Wei W, Jian PE, Li SH, Guo ZX, Zhang YF, Ling YH et al (2018) Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. Cancer Commun (Lond) 38(1):61

    PubMed  Google Scholar 

  19. Okusaka T, Okada S, Ueno H, Ikeda M, Shimada K, Yamamoto J, Kosuge T, Yamasaki S, Fukushima N, Sakamoto M (2002) Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer 95(9):1931–1937

    Article  PubMed  Google Scholar 

  20. Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 76(3):681–693

    Article  PubMed  Google Scholar 

  21. Benson AB, D’Angelica MI, Abbott DE, Anaya DA, Anders R, Are C et al (2021) Hepatobiliary cancers, Version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19(5):541–565

    Article  PubMed  Google Scholar 

  22. Rong W, Yu W, Wang L, Wu F, Zhang K, Chen B et al (2020) Adjuvant radiotherapy in central hepatocellular carcinoma after narrow-margin hepatectomy: a 10-year real-world evidence. Chin J Cancer Res 32(5):645–653

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Yu W, Wang W, Rong W, Wang L, Xu Q, Wu F, Liu L, Wu J (2014) Adjuvant radiotherapy in centrally located hepatocellular carcinomas after hepatectomy with narrow margin (<1 cm): a prospective randomized study. J Am Coll Surg 218(3):381–392

    Article  PubMed  Google Scholar 

  24. Long L, Chen B, Wang H, Zhao Y, Wu F, Wang L, Rong W, Wu J, Li Y, Wang W (2023) Survival benefit of radiotherapy following narrow-margin hepatectomy in patients with hepatocellular carcinoma: a propensity score-matched analysis based on phase II study. Radiother Oncol 180:109462

    Article  CAS  PubMed  Google Scholar 

  25. Wang L, Ke Q, Lin K, Chen J, Wang R, Xiao C, Liu X, Liu J (2020) Not all hepatocellular carcinoma patients with microvascular invasion after R0 resection could be benefited from prophylactic transarterial chemoembolization: a propensity score matching study. Cancer Manag Res 12:3815–3825

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Xi T, Lai EC, Min AR, Shi LH, Wu D, Xue F et al (2012) Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: a non-randomized comparative study. Hepatogastroenterology 59(116):1198–1203

    PubMed  Google Scholar 

  27. Ren ZG, Lin ZY, Xia JL, Ye SL, Ma ZC, Ye QH, Qin LX, Wu ZQ, Fan J, Tang ZY (2004) Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. World J Gastroenterol 10(19):2791–2794

    Article  PubMed  PubMed Central  Google Scholar 

  28. Bai S, Yang P, Liu J, Xue H, Xia Y, Liu F et al (2023) Surgical margin affects the long-term prognosis of patients with hepatocellular carcinoma undergoing radical hepatectomy followed by adjuvant TACE. Oncologist 28(8):e633–e644

    Article  PubMed  PubMed Central  Google Scholar 

  29. Bai T, Chen J, Xie ZB, Wu FX, Wang SD, Liu JJ, Li LQ (2016) The efficacy and safety of postoperative adjuvant transarterial embolization and radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombus. Onco Targets Ther 9:3841–3848

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Wang L, Chen B, Li Z, Yao X, Liu M, Rong W et al (2019) Optimal postoperative adjuvant treatment strategy for HBV-related hepatocellular carcinoma with microvascular invasion: a propensity score analysis. Onco Targets Ther 12:1237–1247

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Wang W, Feng X, Zhang T, Jin J, Wang S, Liu Y, Song Y, Liu X, Yu Z, Li Y (2010) Prospective evaluation of microscopic extension using whole-mount preparation in patients with hepatocellular carcinoma: Definition of clinical target volume for radiotherapy. Radiat Oncol 5:73

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study is supported by the Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Ministry of Education (GKE-ZZ202216); Key Laboratory of High-Incidence-Tumor Prevention and Treatment of the Ministry of Education (GKE-ZZ202129); Key Laboratory of High-Incidence-Tumor Prevention and Treatment of the Ministry of Education (GKE-ZZ202004); Guangxi Medical University Training Program for Distinguished Young Scholars.

Author information

Author notes

  1. Tao Bai and Zhi-hong Tang contributed equally to this work as Co-first authors.

Authors and Affiliations

  1. Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China

    Tao Bai, Zhi-hong Tang, Xiao-bo Wang, Jie Chen, Jia-zhou Ye, Shao-long Lu, Meng Wei, Fei-xiang Wu & Le-qun Li

  2. Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor(Guangxi Medical University), Nanning, Guangxi, China

    Fei-xiang Wu

Authors
  1. Tao Bai
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Zhi-hong Tang
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Xiao-bo Wang
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Jie Chen
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Jia-zhou Ye
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Shao-long Lu
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Meng Wei
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. Fei-xiang Wu
    View author publications

    You can also search for this author inPubMed Google Scholar

  9. Le-qun Li
    View author publications

    You can also search for this author inPubMed Google Scholar

Contributions

Tao Bai, Zhi-hong Tang conceived the study. Xiao-bo Wang extracted all dada. Jie Chen, Jia-zhou Ye undertook and refined the searches. Shao-long Lu, Meng Wei undertook the statistical analyses. Fei-xiang Wu, Le-qun Li wrote the paper. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Fei-xiang Wu or Le-qun Li.

Ethics declarations

Ethics approval

This study was approved by the Ethics Committee of the Guangxi Medical University Cancer Hospital (No. LW2023107). All patients provided written informed consent. All methods were carried out in accordance with the Declaration of Helsinki.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bai, T., Tang, Zh., Wang, Xb. et al. Radiotherapy is superior to transarterial chemoembolization as adjuvant therapy after narrow-margin hepatectomy in patients with hepatocellular carcinoma: A single-center prospective randomized study. Langenbecks Arch Surg 409, 97 (2024). https://doi.org/10.1007/s00423-024-03249-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00423-024-03249-4

Keywords